REGENXBIO, a clinical-stage biotechnology company based in Rockville, Maryland, specializes in gene therapy using its NAV Technology Platform for retinal, neuromuscular, and neurodegenerative diseases. Its key therapies include ABBV-RGX-314, RGX-202, and RGX-121.
Regenxbio (RGNX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Regenxbio's actual EPS was -$1.01, beating the estimate of -$1.17 per share, resulting in a 13.65% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
